(Reuters) – Britain’s Smiths Group
The London-listed company said it has agreed with biopharmaceutical firm Attomarker, for an undisclosed amount, to make its portable, triple antibody test device at unit Smiths Detection’s site in Hemel Hempstead, England.
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Bernard Orr)


